Wednesday, December 9, 2020

Detailed data on AstraZeneca-Oxford Covid-19 vaccine show it has moderate efficacy

Kirsty Wigglesworth/AP

Helen Branswell

The Covid-19 vaccine being developed by the University of Oxford and AstraZeneca appears to have moderate efficacy in preventing symptomatic illness, and may significantly reduce hospitalization from the disease, data from four clinical trials of the vaccine reveal.

The highly anticipated publication of the data, released Tuesday in The Lancet, also point to some signals that deserve further exploration — the possibility of protection after a single dose and the suggestion that at least one dosing regimen may have led to a decrease the number of asymptomatic infections.

“This warrants — it’s screaming for — more work in this area,” vaccine researcher Saad Omer, director of Yale University’s Institute of Global Health, said of the hint the vaccine may reduce asymptomatic infections. “You can’t ignore the results but you have to be judicious about moving forward.”  Read more >>